CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
CT041 autologous CAR T-cell injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05911217
NCT05911217Phase 1RecruitingOn TrackUpdated 25mo ago
CompareCT.gov

An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer

CARsgen Therapeutics Co., Ltd.·interventional·Posted Jun 20, 2023·Updated May 28, 2024

In Brief

A Phase 1 clinical trial evaluating CT041 autologous CAR T-cell injection for Pancreatic Cancer. Currently recruiting, targeting 20 participants across 8 sites.

Detailed Summary

An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesChina
CollaboratorsFudan University

Timeline

Phase 1Recruiting
2024202520262027
First PostedJun 20, 2023
Enrollment StartJul 11, 2023
Primary CompletionDec 31, 2026
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 3.0 years agoPrimary completion in 6 months

Interventions

CT041 autologous CAR T-cell injectiondrug

Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion